Can a shot into the tumor help fight breast cancer?

NCT ID NCT07319195

Recruiting now Disease control Sponsor: Jennifer Zhang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests two immune-boosting drugs—Mitazalimab and Nivolumab—injected directly into breast tumors before surgery. The goal is to see if this approach is safe and can activate the immune system to fight the cancer. About 32 adults with resectable breast cancer will receive one dose 7 or more days before their scheduled surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mitazalimab (CD40 agonist) and Nivolumab (PD-1 inhibitor)
What this could lead to: If successful, this could point toward a new way to activate the immune system against breast cancer before surgery, potentially reducing recurrence risk.
What could go wrong: This is a very early (Phase 1) trial with only 32 participants, so safety and immune effects are still unknown. The treatment may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Hospital of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.